Trials / Completed
CompletedNCT00092625
Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-803)
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of Ezetimibe 10 mg or Placebo Added to Existing Atorvastatin 10 mg or 20 mg in Attaining Low-Density Lipoprotein Cholesterol Target Levels in Patients With Hypercholesterolemia and Coronary Heart Disease.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 442 (actual)
- Sponsor
- Organon and Co · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate additional cholesterol lowering effects in patients with coronary heart disease by giving an investigational drug with a patient's current approved cholesterol lowering medication.
Detailed description
The duration of treatment is 10 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK0653, ezetimibe | |
| DRUG | Comparator: ezetimibe, placebo |
Timeline
- Start date
- 2003-03-01
- Primary completion
- 2004-07-01
- Completion
- 2004-08-01
- First posted
- 2004-09-27
- Last updated
- 2024-08-15
Source: ClinicalTrials.gov record NCT00092625. Inclusion in this directory is not an endorsement.